We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron Wins EC Clearance for Libtayo Dosing Flexibility
Read MoreHide Full Article
Key Takeaways
Regeneron secured EU approval for flexible Libtayo dosing across all six approved cancer indications.
The new 700 mg six-week schedule could reduce clinic visits and treatment time for patients.
REGN's growth is supported by Eylea HD, Dupixent and oncology pipeline progress
Regeneron Pharmaceuticals (REGN - Free Report) announced that the European Commission (EC) has approved a more flexible dosing schedule for its cancer drug Libtayo (cemiplimab) across all six approved skin, lung and cervical cancer indications in the European Union.
The approval allows patients who have completed the initial 12 weeks of treatment with Libtayo 350 mg every three weeks to switch to a higher 700 mg dose administered every six weeks, with each infusion lasting 30 minutes.
Additionally, patients who tolerate their first 30-minute infusion of the 350 mg dose can receive subsequent infusions over 15 to 30 minutes.
The revised dosing options could reduce the frequency of clinic visits and treatment time, improving convenience for patients and caregivers while offering greater flexibility to healthcare providers.
The approval is supported by safety and efficacy data from Libtayo’s clinical development program, along with pharmacokinetic and pharmacodynamic modeling and simulation data. It covers all six of Libtayo’s approved indications in the EU, spanning advanced cutaneous squamous cell carcinoma (CSCC), adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation, basal cell carcinoma, non-small cell lung cancer (NSCLC) and recurrent or metastatic cervical cancer.
The approval is a positive development for Regeneron, as greater dosing flexibility could improve the treatment experience, support patient convenience and potentially strengthen Libtayo's competitive positioning in the oncology market.
Libtayo is also an important component of the company's broader oncology strategy, serving as the backbone for several investigational combination therapies.
Meanwhile, a supplemental Biologics License Application seeking approval of the alternative dosing regimen in the United States is under FDA review, with a decision expected in March 2027.
An approval in the United States could provide an additional opportunity to enhance Libtayo's commercial appeal.
REGN’s Robust Performance
REGN has put up a strong year-to-date performance. Shares have rallied 24.1% compared with the industry’s gain of 6.5%.
Image Source: Zacks Investment Research
The rally followed strong quarterly results, as solid demand for Eylea HD, the higher-dose version of Eylea, and higher profit-sharing from Dupixent helped offset declining sales of standard-dose Eylea.
Eylea HD is gaining traction, supported by steady label expansions.
REGN’s top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi (SNY - Free Report) records global net product sales of Dupixent.
Ongoing label expansions for Dupixent continue to drive strong sales growth and contribute meaningfully to profitability.
Progress across its oncology portfolio should support greater diversification of revenues and reduce reliance on any single franchise. The recent pipeline momentum and favorable regulatory developments have improved the outlook.
Its deep pipeline, including the potential launch of cemdisiran for generalized myasthenia gravis, provides additional growth opportunities.
Meanwhile, CytomX Therapeutics (CTMX - Free Report) announced the achievement of a preclinical milestone for one of the lead programs under its collaboration with REGN, triggering a $5 million milestone payment to the former.
REGN has collaborated with CytomX on discovery activities to identify and validate conditionally active bispecific antibodies. Per the terms, Regeneron will be responsible for funding all preclinical and clinical development, as well as commercialization activities. CytomX is eligible to receive target nomination payments and preclinical, clinical, regulatory and commercial milestone payments totaling up to approximately $4 billion under the expanded agreement.
Image: Bigstock
Regeneron Wins EC Clearance for Libtayo Dosing Flexibility
Key Takeaways
Regeneron Pharmaceuticals (REGN - Free Report) announced that the European Commission (EC) has approved a more flexible dosing schedule for its cancer drug Libtayo (cemiplimab) across all six approved skin, lung and cervical cancer indications in the European Union.
The approval allows patients who have completed the initial 12 weeks of treatment with Libtayo 350 mg every three weeks to switch to a higher 700 mg dose administered every six weeks, with each infusion lasting 30 minutes.
Additionally, patients who tolerate their first 30-minute infusion of the 350 mg dose can receive subsequent infusions over 15 to 30 minutes.
The revised dosing options could reduce the frequency of clinic visits and treatment time, improving convenience for patients and caregivers while offering greater flexibility to healthcare providers.
The approval is supported by safety and efficacy data from Libtayo’s clinical development program, along with pharmacokinetic and pharmacodynamic modeling and simulation data. It covers all six of Libtayo’s approved indications in the EU, spanning advanced cutaneous squamous cell carcinoma (CSCC), adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation, basal cell carcinoma, non-small cell lung cancer (NSCLC) and recurrent or metastatic cervical cancer.
The approval is a positive development for Regeneron, as greater dosing flexibility could improve the treatment experience, support patient convenience and potentially strengthen Libtayo's competitive positioning in the oncology market.
Libtayo is also an important component of the company's broader oncology strategy, serving as the backbone for several investigational combination therapies.
Meanwhile, a supplemental Biologics License Application seeking approval of the alternative dosing regimen in the United States is under FDA review, with a decision expected in March 2027.
An approval in the United States could provide an additional opportunity to enhance Libtayo's commercial appeal.
REGN’s Robust Performance
REGN has put up a strong year-to-date performance. Shares have rallied 24.1% compared with the industry’s gain of 6.5%.
Image Source: Zacks Investment Research
The rally followed strong quarterly results, as solid demand for Eylea HD, the higher-dose version of Eylea, and higher profit-sharing from Dupixent helped offset declining sales of standard-dose Eylea.
Eylea HD is gaining traction, supported by steady label expansions.
REGN’s top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi (SNY - Free Report) records global net product sales of Dupixent.
Ongoing label expansions for Dupixent continue to drive strong sales growth and contribute meaningfully to profitability.
Progress across its oncology portfolio should support greater diversification of revenues and reduce reliance on any single franchise. The recent pipeline momentum and favorable regulatory developments have improved the outlook.
Its deep pipeline, including the potential launch of cemdisiran for generalized myasthenia gravis, provides additional growth opportunities.
Meanwhile, CytomX Therapeutics (CTMX - Free Report) announced the achievement of a preclinical milestone for one of the lead programs under its collaboration with REGN, triggering a $5 million milestone payment to the former.
REGN has collaborated with CytomX on discovery activities to identify and validate conditionally active bispecific antibodies. Per the terms, Regeneron will be responsible for funding all preclinical and clinical development, as well as commercialization activities. CytomX is eligible to receive target nomination payments and preclinical, clinical, regulatory and commercial milestone payments totaling up to approximately $4 billion under the expanded agreement.
REGN currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.